Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
DiogenX logo — Targeting Beta Cell recovery in Diabetes

DiogenX

Targeting Beta Cell recovery in Diabetes

Founded 2020 France France 24 employees Series A Total: $38.00M

General Information

Company Name DiogenX
Founded Year 2020
Location France France
Founders / Decision Makers
Team member
Employees 24
Funding Stage Series A
Business Model B2B, White Label
Revenue Model Licensing, Product Sales, Value Based Pricing
Social

BounceWatch is an independent company data service, not affiliated with DiogenX. To contact DiogenX, visit diogenx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does DiogenX compare?

A PDF of DiogenX and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting DiogenX soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About DiogenX

DiogenX, founded in 2020, is a preclinical-stage biotech company based in France, with headquarters in Marseille and labs in Nice. The company operates under the slogan "Targeting Beta Cell recovery in Diabetes," reflecting its commitment to developing innovative biologics aimed at offering new therapeutic options for diabetes management.

DiogenX's lead program, rooted in laboratory research by Dr. Patrick Collombat, targets the functional recovery of beta cells to address beta-cell failure, a fundamental challenge in diabetes treatment. This groundbreaking approach aims to optimize glucose/insulin homeostasis, offering significant clinical benefits to diabetic patients.

The company recently secured a €6.00M Series A investment from Sunstone Life Science Ventures on 01 November 2023. This capital infusion is crucial for advancing preclinical developments and potentially transitioning toward clinical trials, positioning DiogenX as a promising player in the biotech space.

Business keywords: biotech, preclinical stage, beta-cell recovery, diabetes therapeutics, Type 1 Diabetes, Type 2 Diabetes, insulin-producing cells, pancreatic beta-cell modulators, insulin homeostasis, novel biologics, collaborative research, clinical innovation, regenerative medicine, beta-cell regeneration, therapeutic development

Services & Products

Discovery and Development of Biologics
Regenerative Treatment for Type 1 Diabetes

Target Customers

Diabetic Patients Healthcare Professionals Research and Development Organizations

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series A €6.00M 1
Sunstone Life Science Ventures
01 Nov 2023
Grant €27.50M 6
Omnes Capital Boehringer Ingelheim Eli Lilly
Omnes Capital, Boehringer Ingelheim +4
01 May 2023
Seed €4.50M 3
Boehringer Ingelheim
Boehringer Ingelheim, JDRF T1D Fund +1
01 Jun 2020
Spinout Undisclosed 4
University Ventures CNRS Innovation
University Ventures, CNRS Innovation +2
01 Jan 2019

DiogenX Alternatives & Competitors

View All Alternatives
DiogenX vs
Sidansai
Sidansai

A Shanghai-based biotechnology company pioneering the advancement of cell therapy.

Series C
2 employees
Biotechnology, Health Care
DiogenX vs
Aurion Biotech
Aurion Biotech United States

We're on a mission to cure blindness with our transformational platform of advanced therapies

Acquired
94 employees
Biopharma, Biotechnology
DiogenX vs
Histide
Histide Switzerland

Histide uses non-mutagenic CRMs to stimulate a cell's natural capacity to redirect its own fate, cre...

Series A
6 employees
Biotechnology, Health Care
View all alternatives

FAQ About DiogenX

Targeting Beta Cell recovery in Diabetes
DiogenX was founded in 2020.
DiogenX is headquartered in France.
DiogenX has a B2B and White Label business model. Its revenue comes from Licensing, Product Sales and Value Based Pricing.
DiogenX has approximately 24 employees.
DiogenX has completed 4 funding rounds, raising a total of $38.00M. The latest funding stage is Series A.
DiogenX offers: Discovery and Development of Biologics, Regenerative Treatment for Type 1 Diabetes.
Top alternatives and competitors to DiogenX include Sidansai, Aurion Biotech, Histide, Bridge Medicines LLC, Microviable Therapeutics SL. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
DiogenX and Sidansai are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for DiogenX, https://bouncewatch.com/company/diogenx, updated 11 May 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout